Cryo-Cell Intl Inc Stock Price, News & Analysis

Cryo-Cell International, Inc. (CCEL) announced its fiscal first-quarter results for the period ending February 28, 2023. The company reported revenues of $7.82 million, a notable increase from $7.26 million during the same period in 2022. Key revenue components included $7.56 million from processing and storage fees, $32,000 in product revenue, and approximately $231,000 from public banking efforts.

Net income for the quarter was approximately $767,000, or $0.09 per share, slightly down from $832,000 or $0.10 per share a year earlier. The increase in revenue was offset by a 15% rise in selling, general, and administrative expenses. The company remains focused on its transformation into a vertically integrated cellular therapy company.

Cryo-Cell International (CCEL) reported fiscal 2022 results with consolidated revenues of $30.3 million, up from $28.9 million in fiscal 2021. Processing and storage fees led revenue at $29.8 million. Net income grew to $2.8 million or $0.33 per share, compared to $2.1 million or $0.26 per share in 2021. Key factors included a 5% increase in revenue and a 2% decrease in the cost of sales. The company continues to expand services, including a partnership with Duke University and the launch of ExtraVault, enhancing its biostorage capabilities.

Cryo-Cell International (CCEL) reported a 3% revenue increase in Q3 2022, reaching $7.7 million, compared to $7.5 million in Q3 2021. Processing and storage fees accounted for the majority at $7.5 million. However, net income decreased to $467,000 ($0.06 per share) from $857,000 ($0.10 per share) year-over-year. Cost of sales fell by 4%, while SG&A expenses rose by 3%. The company highlights its partnerships and advanced processing technologies as core strengths.

Cryo-Cell International, Inc. (CCEL) has announced a special cash dividend of $0.90 per share for shareholders of record as of September 2, 2022. The decision reflects the Board's commitment to reward long-term investors while advancing its cellular therapies using cord blood and tissue. Founded in 1989, Cryo-Cell is renowned as the first private cord blood bank and has handled over 500,000 samples globally. The company also engages in clinical applications and has partnered with Duke University for public banking.

Cryo-Cell International, Inc. (CCEL) will transition its stock listing from the Nasdaq Capital Market to the NYSE American on August 30, 2022. Chairman David Portnoy believes this move will enhance trading liquidity for shareholders. The last trading date on Nasdaq is expected to be August 29, 2022. Founded in 1989, Cryo-Cell is renowned for being the first private cord blood bank, with over 500,000 parents utilizing its services globally. The company holds numerous accreditations and a partnership with Duke University, emphasizing its commitment to advanced cellular therapies.